Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）

Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） is a phase 2/3, randomised interventional study registered as NCT07076693 by Shanghai Chest Hospital, with a registry enrolment figure of 97 participants, started 2025-06-03 and due to reach its primary completion in 2028-05-31. Interventions recorded: Radiotherapy or Surgery; Standard Medical Therapy. Conditions listed: OligoProgressive Metastatic Disease; Non-Small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR); Progression-free survival (PFS). Lung eligibility wording from the registry: "For Epidermal Growth Factor Receptor (EGFR)-sensitive mutant non-squamous NSCLC patients, first-line treatment must be the third-generation TKIs or progression after first/second-generation TKI without harboring T790M mutation, with ≤3 progressive lesions and ≤3 metastatic organs (PET-CT + cranial M". Sites: China. No results are recorded here; the registry entry is the source.